Among the various cancers arising in MSH2 and MLH1 mutation carriers, the highest lifetime risk is for colorectal cancer, followed by endometrial cancer and other extracolonic cancers; moreover, MSH2 mutations may be associated with higher risks of extracolonic cancers compared to MLH1 mutations [48, 51]. This evidence concerns the gene MSH2 and cancer.